secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001628280-26-031643
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs Q1 net loss $14.8M; Phase 1 SL-325 enrollment complete, data Q2 2026
--------------------------------------------------------------------------------

- Cash and equivalents $90.4M as of March 31, 2026, up from $60.9M a year ago; cash runway into 2029 assuming warrant exercise.
- Phase 1 trial of SL-325 (DR3 blocking antibody) enrollment complete; safety, PK, PD data expected Q2 2026.
- Phase 2 trial in Crohn's disease expected to initiate Q3 2026, subject to positive Phase 1 data and regulatory alignment.
- Net loss $14.8M ($0.13 per share) vs $13.7M ($0.27) in Q1 2025; R&D expenses $10.9M vs $9.9M.
- Lead bispecific DR3 antibody in IND-enabling activities; target disclosure and preclinical data expected Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000162828026031643/0001628280-26-031643-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000162828026031643/sttk-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-031643

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer